TAC与TC新辅助化疗方案治疗局部晚期乳腺癌疗效比较

Comparison of clinical efficacy of neoadjuvant chemotherapy regimens of TA（ docetaxel ＋ pirarubicin cyclophosphamide） vs. TC （ docetaxel＋ cyclophosphamide） for locally advanced breast cancer

目的比较TAC与TC新辅助化疗方案治疗局部晚期乳腺癌的临床疗效和不良反应。方法经病理等检查确诊局部晚期乳腺癌患者257例，随机分为TAC组（130例）及TC组（127例），分别给予TAC方案、TC方案化疗4个周期。TAC组129例、TC组124例化疗结束2周后行乳腺癌改良根治术。比较TAC组、TC组疗效和不良反应，治疗前、后TNM分期变化及术后并发症。结果临床疗效比较TAC组优于TC组，其差异有统计学意义（P〈0．05）；TNM分期较新辅助化疗前降低（P〈0．05），不良反应比较差异无统计学意义（P〉0．05）；术后并发症比较差异无统计学意义（P〉0．05）。结论TAC及TC新辅助化疗方案对局部晚期乳腺癌均有效，TAC方案优于TC方案．

Objective To observe the clinical efficacy and adverse reactions of neoadjovant chemotherapy regimens of TAC （ doeetaxel ＋ pirarubiein ＋ eyclophosphamide ） and TC （ docetaxel ＋ cyclo phosphamide） in the treatment of locally advanced breast cancer （ LABC ）. Methods A total of 257 pa tients with LABC diagnosed by pathology were randomly divided into the TC group（ 127 cases）and the TAC group（ 130 cases）. These patients were treated with TC or TAC for 4 cycles respectively. Two weeks after the chemotherapy, 124 cases in the TC program and 129 cases in the TAC program received modified radical mastectomy later. The efficacy, adverse reactions, TNM classification and postoperative complica tions were compared between the two groups. Results The clinical effect of TAC group was better than that of TC group and the difference was statistically significant; The TNM stage of both groups was im proved after the neoadjuvant chemotherapy（ P 〈0.05） , and the differences in adverse reactions and post operative complications were not significant between the groups. Conclusion TAC and TC are both effec tive to treat LABC,and TAC is superior to TC.